Pascal Soriot, AstraZeneca CEO (David Zorrakino/Europa Press via AP)
September 13, 2022 02:29 PM EDTUpdated 03:26 PM
Pharma
Law

As­traZeneca wins fed­er­al class-ac­tion suit, judge dis­miss­es share­hold­er­s' mis­lead­ing claims

Paul Schloesser

Associate Editor

As­traZeneca nev­er got its Covid-19 vac­cine au­tho­rized in the US, and while share­hold­ers have tried tak­ing the UK phar­ma to court, a judge has now …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Blue­bird bio to sell to in­vest­ment funds af­ter strug­gling to make mon­ey from gene ther­a­pies

CBER's deputy di­rec­tor de­parts as staff shake­up con­tin­ues

Eli Lil­ly stock­piles $548M of oral weight loss drug ahead of launch

Will CRISPR mat­ter?

FDA ap­proves first drug to treat ul­tra-rare lipid stor­age dis­ease

sponsored

Trust­ed pro­tec­tion: Why the cur­rent meningo­coc­cal vac­ci­na­tion sched­ule shouldn’t change with­out strong ev­i­dence

A service from the Financial Times